Daiichi Sankyo Overhauls European Leadership as Part of Global Commercialization Push
Event summary
- Markus Kosch appointed Head of Europe Business, effective April 1, 2027, leading the new globally integrated Commercialization Unit.
- Kosch will oversee Oncology and Specialty businesses in Europe under a unified leadership model.
- Appointment aligns with Daiichi Sankyo’s Five-Year Business Plan to streamline commercialization and support multiple new indication launches by 2030.
- Kosch brings five years of experience leading Daiichi Sankyo’s Oncology Business Division in Europe and Canada.
The big picture
Daiichi Sankyo’s restructuring of its European business reflects a broader industry trend toward streamlined commercialization and regional integration. The move is critical as the company prepares to launch multiple new indications by 2030, leveraging its strength in oncology. The appointment of Kosch, with his dual background in medical practice and commercial leadership, underscores the company’s focus on blending scientific innovation with operational execution.
What we're watching
- Integration Challenges
- How effectively Kosch can merge Oncology and Specialty businesses under one leadership model.
- Portfolio Execution
- The pace at which Daiichi Sankyo advances its antibody drug conjugate portfolio in Europe.
- Regional Strategy
- Whether the new structure enhances Daiichi Sankyo’s ability to compete in the European pharmaceutical market.
Related topics